MAPT and Alzheimer disease: Investigations have demonstrated that staggered administration of STZ results in a sustained hyperglycaemic state with induction of learning and memory deficits, increased tau phosphorylation and increased neuroinflammation in mice consistent with AD pathological changes (Murtishaw et al., 2018).